The California Environmental Biomonitoring Program (also known as Biomonitoring California) has been generating human biomonitoring data and releasing it via their website. The current Biomonitoring California program is a collection of smaller studies, targeting specific populations (e.g., fire fighters, breast cancer patients and controls, etc.). In this paper we compare the results from Biomonitoring California with those from the US National Health and Nutrition Examination Survey (NHANES). We also compare California's results with Biomonitoring Equivalents (BEs) for those compounds for which BEs exist. In general, the results from California are consistent with the biomonitoring levels found across the US via NHANES. A few notable exceptions are levels of flame retardants amongst fire fighters in California, which are higher than observed in NHANES and some persistent organic chemicals amongst a study of breast cancer patients and controls in California which are higher than in the overall adult population in NHANES. The higher levels amongst fire fighters may be a result of fire fighters being exposed to higher levels of flame retardants while fighting fires. The higher levels of the persistent organics amongst breast cancer patients is likely due to this population being older than the mean age in NHANES. Comparisons to BEs indicate that biomonitoring levels in California are all consistently below levels of concern as established by regulatory agencies.
establish trends over time, and assess effectiveness of programs designed to decrease exposures to specific chemicals. The program includes a robust public communication and participation component through thrice-yearly public meetings of the California Biomonitoring Program's Scientific Guidance Panel (SGP) and a responsive and extensive website (http://biomonitoring.ca.gov).
To date, the program has indicated that it has not been funded to a level that allows a full execution of the goals and aims of the program (see meeting minutes from the public meetings over the past several years at http://biomonitoring.ca.gov). The limitations imposed by the funding issues manifest in two ways. First, the list of Designated Chemicals of interest compiled through an iterative process with the SGP remains largely an aspirational list. While the list includes more than 500 specific chemicals as well as several chemical groups without specific enumeration of the chemicals included, the program has reported results for approximately 140 chemicals across several independent studies (not all chemicals monitored in all studies) (http://biomonitoring.ca.gov/chemicals/ chemicals-biomonitored-california). Second, until very recently, the program has not been able to undertake a sampling effort that is "representative" of the California population. Instead, the program has strived to identify and interact with ongoing studies in California that are examining various targeted populations and that incorporate a biomonitoring component. Data are being generated through independent studies for chemicals that are the subject of the specific hypotheses in those studies, and although the analytes may overlap to some degree with the Designated Chemicals list, there is no current effort to comprehensively measure the full list of Designated Chemicals in studies in California. 1 As of October 2014 there were no results available from a study attempting statistically representative sampling of the California population for age, gender, geography, or other representative basis. The California Biomonitoring Program has recently launched a pilot and expanded study entitled Biomonitoring Exposures Study (BEST) through a partnership with a managed care organization in the Central Valley of California to more closely approach the ideal of a representative study (http://biomonitoring.ca.gov/projects/ biomonitoring-exposures-study-best-1pilot). However, as of the date of data collection for this paper, results are not yet available from either the pilot or expanded BEST studies. Instead, the Biomonitoring California program has organized and made available summary statistics from a variety of targeted studies in California that report biomonitoring data carried out by others, as noted above.
Although the program is ongoing and results continue to be reported out from ongoing studies, the Biomonitoring California program now has posted a substantial body of results on their website (http://biomonitoring.ca.gov/results/explore). The results are reported as summary statistics, and raw data are not available. Making use of this data, we provide a comparison of the reported results from studies collected at the Biomonitoring California website as of October 2014 to results from the US National Health and Nutrition Examination Survey (NHANES) program. In addition, in a manner analogous to previous activities to interpret US NHANES and the Canadian Health Measures Survey (CHMS) biomonitoring data, the California biomonitoring results are interpreted in a public health risk context using Biomonitoring Equivalents (BEs) and other similar risk-based biomonitoring evaluation values (Aylward et al., 2013; St-Amand et al., 2014) . Riskbased interpretations are made using BEs, which are estimates of concentrations of a chemical or its metabolites in a biological matrix (e.g., blood, urine) corresponding to an exposure guidance value such as an EPA reference dose (RfD) or tolerable daily intake (TDI) (Angerer et al., 2011; Hays et al., 2007 Hays et al., , 2008 . These comparisons can be used to inform both evaluations of potential risks from chemical exposures in the California population and the design and focus of future studies in California.
Methods

Biomonitoring California program data
Summary statistics for all projects with reported results were downloaded from the Biomonitoring California website on October 27, 2014. The results included those from seven independent biomonitoring studies (Table 1) and encompass analytes from numerous chemical classes including legacy organochlorine pesticides (OCPs), polybrominated diphenyl ethers (PBDEs), current use pesticides, metals, polychlorinated biphenyls (PCBs), polycyclic aromatic hydrocarbons (PAHs), polyfluoroalkyl compounds (PFAS), environmental phenols, phthalate esters, and a benzophenone derivative in widespread use in sunscreen preparations. Data from each study remain in the custody of the study teams; summaries of results are reported to the Biomonitoring CA program and made available on the Biomonitoring CA website. Thus, raw data from the independent studies are not available for analysis. Geometric means for the datasets were reported only when detection rates exceeded 65%.
NHANES program data
Summary statistics for analytes from the US NHANES biomonitoring program were downloaded from the CDC webpage. Specifically, updated tables from the Fourth National Exposure Report (CDC, 2014) were used to extract geometric mean and confidence interval estimates for population groups corresponding to those examined in the California studies (see Table 1 ). The best available match for demographic (e.g., females or adults) and year of sampling was selected. For selected persistent organic pollutants (POPs), statistics reported for specific age groups were obtained from Patterson et al. (2009) .
Comparisons between the CA study results and NHANES focused on comparison of geometric means and their associated confidence intervals. Formal statistical comparisons were not attempted because of certain limitations: the raw data from the CA studies were not available; the specific age and in some cases gender compositions of the CA studies were not available; and no indication of population representativeness with respect to variables considered in the NHANES sampling protocols were available. Comparisons at higher population percentiles (e.g., the 95th percentile) were not made because in general the studies presented on the CA Biomonitoring program website were relatively small (<200 individuals), and although 90 th or 95th percentile estimates were reported, no confidence intervals on those values were calculated or reported. As a result, a valid comparison to NHANES upper percentiles was not possible. In addition, for non-persistent chemicals such as the phthalates, environmental phenols, parabens, and some of the pesticides. Both lower and upper bounds of distributions of spot sample concentrations are likely to be relatively unstable due to large intra-individual variation in biomarker concentrations for such compounds (Aylward et al., 2012) . Thus, comparisons at central tendencies provide a more stable assessment of relative population exposure levels.
Risk assessment-based interpretation
Information on pharmacokinetics has previously been used to estimate biomarker concentrations that are consistent with existing exposure guidance values such as EPA RfDs, or Health Canada TDIs, or similar values (reviewed in Aylward et al., 2013) . These biomonitoring based assessment values have variously been called Biomonitoring Equivalents (BEs; Hays et al., 2007 Hays et al., , 2008 or Human Biomonitoring values (HBM values; Angerer et al., 2011) . These values can be used as screening tools to evaluate whether biomarker concentrations are signaling exposures that are well below, near, or at or above levels consistent with population level risk assessment-based exposure guidance values.
The BE values and other similar guidance values are generally estimates of steady-state or average biomarker concentrations corresponding to an intake exposure guidance value that has been developed for chronic exposures. For example, a BE derived from an 1 Biomonitoring California has recently received an additional grant from the Centers for Disease Control (CDC) and Prevention that will support expansion of their goals (http://biomonitoring.ca.gov/biomonitoring-california-awarded-5m-centers-disease-control). Biomonitoring California states they will "use the funding during the first year to establish statewide surveillance for environmental contaminants in maternal serum samples".
EPA oral RfD would be used to interpret biomonitoring results in a manner analogous to the way the RfD is used to interpret human oral exposures. For example, a health risk based interpretation of oral exposures involves comparing the estimated average daily lifetime intake in mg/kg-day to the oral RfD, where the oral RfD is defined as "an estimate [of oral exposure in mg/kg-day] (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime" (EPA glossary http://www.epa.gov/risk_ assessment/glossary.htm#r). Using knowledge of toxicokinetics, a BE can be developed from a RfD, resulting in a health risk-based guidance value in units of concentration (in urine or blood) that corresponds to the applied dose RfD value. Thus, a BE RfD can be viewed as to the average daily lifetime concentration value (in blood or urine) "that is likely to be without appreciable risk of deleterious effects in a lifetime," in the population, including sensitive subgroups. Human biomonitoring data can be interpreted in a population human health risk context by comparing the measured levels (in blood or urine) to the corresponding BE. Measured biomarker concentrations far below the corresponding BE value suggest that exposures are generally well below levels deemed tolerable in a risk assessment context. Measured biomarker concentrations near or above the BE value indicate exposures may be approaching or exceeding risk assessment-based guidance values.
This framework must be considered in the interpretation of distributions of biomarker concentrations in spot samples collected randomly from populations. For highly persistent compounds (e.g., legacy organochlorine compounds and some metals), measurements in spot samples are likely to be representative of longer term average concentrations. However, for chemicals that are rapidly absorbed, metabolized, and eliminated in the body, a spot sample concentration may vary widely over the course of a day or from day to day in an individual, depending on the timing of sample collection compared to last exposure to the substance (Aylward et al., 2012; Preau et al., 2010; Ye et al., 2011) . For this reason, extremes of the distributions of concentrations of spot samples for such compounds are unlikely to represent longer-term average concentrations for any individual. For such transient compounds, comparisons to BE values should be conducted for central tendency summary statistics (geometric or arithmetic means) rather than for population extreme values (Aylward et al., 2012 (Aylward et al., , 2013 St-Amand et al., 2014) .
Results
Comparisons by chemical group
The main comparisons of the California and NHANES datasets are presented as graphs comparing the geometric means and confidence intervals for each chemical group. Only those chemicals with detection rates in both surveys high enough to reliably calculate geometric means are presented and compared. In each graph, estimates of geometric means from each California study reporting data on the Biomonitoring California website for a given analyte are presented paired to the corresponding NHANES subpopulation geometric mean (see Table 1 for description of the specific NHANES subpopulation used for comparison to each of the studies).
Environmental phenols
Data for several environmental phenols and methyl paraben were available from the FOX and MIEEP studies (see Table 1 for study descriptions). Comparison of geometric means between these studies and the NHANES program showed that the spread of confidence intervals on the geometric means in the California studies and the NHANES datasets generally overlapped. The similarity of levels between the California studies and the NHANES dataset suggest that exposures to environmental phenols are similar between the California sub-populations and the general US population (see Fig. 1 ).
Phthalates
Fig. 2 presents the comparative GM values from the various California studies and corresponding NHANES subgroups for phthalate metabolites. In general, GM phthalate metabolite concentrations in urine were similar to those in the comparison NHANES populations. However, for mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), a metabolite of di(2-ethylhexyl) phthalate (DEHP), levels were slightly lower in the FOX study than in the corresponding NHANES comparison group. Levels for mono(3-carboxypropyl) phthalate (MCPP), a metabolite of di-n-octylphthalate, were lower in the MIEEP cohort than in the corresponding NHANES group. Conversely, mono-n-butyl phthalate (MnBP) concentrations were higher in the CHAMACOS cohort, but not in other California studies. The GM for the CHAMACOS cohort (children aged 5) was approximately 50% higher than the NHANES GM for children ages 6 to 11 (the closest corresponding group age, 30.5 vs. 19.5 ng/ml in urine). Available information to determine the underlying differences in children's exposures between the CHAMACOS population and the NHANES population is lacking, although lifestyle factors associated with socio-economic status and ethnicity may be factors to consider (Tyrrell et al., 2013; Zota et al., 2014) .
Differences in the other direction were also observed. The GM for MECPP, a major metabolite of DEHP, was approximately 40% lower in the FOX cohort than in the corresponding NHANES data for adults (12.3 vs. 19 .4 ng/ml) and the GM for MCPP, a metabolite of din-octylpthalate, was threefold lower than the corresponding NHANES GM (0.87 vs. 2.72 ng/ml).
3.1.3. PAHs   Fig. 3 illustrates the comparative urinary PAH concentrations among the California studies and corresponding NHANES groups. In general, the relative pattern of PAH levels are similar between those in the California studies and the NHANES program. There are some differences in GMs for specific PAH metabolites.
1-Hydroxynapthalene (1-NAP) is lower by a factor of 2 or more in both the FOX and MIEEP studies than in the NHANES program. Similarly, 3-hydroxyfluorene (3-FLUO) is also lower in the CA studies. 1-Hydroxyphenanthrene (1-PHEN), 1-hydroxypyrene (1-PYR), 2-hydroxynapthalene (2-NAP), 2-hydroxyphenanthrene (2-PHEN), and 9-hydroxyfluorene (9-FLUO) are higher in one or the other of the two studies examining these markers from California than in NHANES, with differences varying from a factor of about 50e100%. Some caution must be attached to these comparisons because the most recent NHANES cycle with PAH data was the 2007e2008 cycle, while the California data generally come from 2010 to 2011. And while there do not seem to be strong trends in the PAH data in NHANES prior to the 2007e2008 cycle, the GMs in NHANES do seem to vary notably from cycle to cycle for several of these analytes. This likely reflects significant within-and betweenindividual variability in the urinary concentrations of these analytes, in part due to their short elimination half-lives (Li et al., 2010) . Possible differences associated with prevalence of smoking cannot be evaluated since smoking status was not provided as part of the California studies.
Organochlorine pesticides
Measured serum lipid-adjusted concentrations of legacy organochlorine pesticides (Fig. 4) are generally lower in California . The general population in the US has generally demonstrated downward trends in the concentrations of these chemicals with time, so samples taken more recently generally are lower than earlier time points. However, levels in the CTS study are very similar to those reported in the NHANES 2003e2004 dataset for adults of all ages, despite the fact that the samples were taken 7 years later. This may reflect the older age of the CTS study population (discussed further below).
PBDEs
The pattern of comparative PBDE GM concentrations was quite variable among the California studies and in comparison with the NHANES data (Fig. 5) . In general, PBDE concentrations were higher in the FOX and CCLS studies than in the CTS and MIEEP studies. Consistent with that, the GM concentrations of several analytes in the FOX and CCLS studies were higher than the NHANES GMs, while the GM values from the CTS and MIEEP studies were generally lower than or similar to the NHANES GMs. Sampling occurred a few years earlier for the CCLS (2006e2007) compared to the CTS, MIEEP, and FOX studies, in which sampling occurred in 2010e2011.
The most recent NHANES data available for comparison is based on samples collected in 2003e2004. These differences in collection time period might have affected the comparability of levels. In addition, because the FOX cohort is an occupational cohort of firefighters, it is possible that the higher levels in this cohort reflect occupational exposures rather than general environmental exposure levels. However, this does not address the differences between the CCLS and MIEEP studies, both of which examine levels in samples from women of childbearing ages. The CCLS samples were collected somewhat earlier than the MIEEP samples (2006e2007 vs. 2010e2011) but it is not clear that the differences reflect any generalized temporal trend. The NHANES data are not helpful in resolving this issue, as only one time point (2003e2004) is available from NHANES.
PFAAs
PFAAs were measured in the CTS and MIEEP studies (Fig. 6) . In general, levels in these two studies were similar to or lower than those reported in the NHANES program. In the MIEEP program, measured levels were lower for 2-(N-Methyl-perfluorooctane sulfonamido) acetic acid (Me-PFOSA-AcOH) and perfluorooctane sulfonate (PFOS). In the CTS, perfluorohexane sulfonate (PFHxS) concentrations were slightly higher than in NHANES females. 
PCBs
PCB concentrations were measured in four of the California studies (FOX, CTS, CCLS, and MIEEP), and levels compared to the reference NHANES datasets are presented in Fig. 7 . Detections were frequent enough to characterize GM concentrations in most of the studies for a range of PCB congeners. In general, concentrations measured in these studies were lower than the NHANES data, which date from 2003 to 2004, with the exception of the data from the CTS. As with the OCPs, PCBs have generally exhibited a decreasing trend with time in the US, so levels for most of these congeners would be expected to be at least somewhat lower in the CA studies, which collected blood up to 7 years after the most recent NHANES cycle with data. As with the OCPs, the CTS, which is comprised of an older study population, has higher GMs than the other CA studies. This may reflect a difference in age distribution between the CTS study population, which is comprised of breast cancer cases and controls, compared to several other study populations, which are comprised of pregnant women and/or mothers of younger children. However, details on the age distribution in the California studies are not available in order to confirm this.
Metals
Selected metals were measured in urine and blood in the MIEEP project, and in urine only in the FOX project (Fig. 8) . Urinary arsenic levels in the FOX and MIEEP projects (GMs of 10.8 and 7.71 mg/L, respectively) were generally similar to NHANES (GMs of 10.2 mg/L in adults and 8.55 mg/L in females), while urinary cadmium levels in the FOX and MIEEP projects (GMs of 0.145 and 0.185 mg/g creatinine, respectively) were lower than the comparable NHANES data (GMs of 0.242 mg/g creatinine in adults and 0.233 mg/g creatinine in females). For metals in blood, GM levels of cadmium, lead, and mercury were all lower than the corresponding levels in the NHANES program (Fig. 8) .
Current use pesticides
Urinary markers for a number of current use pesticides were measured in several of the California studies. In general, few comparisons could be made due to low detection rates in NHANES or the CA studies. Detection rates were high enough to allow calculation of GMs for TCPy, a metabolite and environmental degradate of chlorpyrifos, in the FOX and MIEEP studies (GMs of 1.8 and 0.5 ng/ml, respectively). These GMs were generally similar to or lower than levels reported in the 2001e2002 NHANES program (1.5 ng/ml). Levels of 3-phenoxybenzoic acid (3-PBA), a nonspecific metabolite of pyrethroid pesticides, in the FOX study (GM of 0.5 ng/ml) were generally similar to the NHANES program (0.4 ng/ml). 
Comparison to exposure guidance values: interpreting California biomonitoring results in a public health risk context
Previously, data from the NHANES and CHMS programs were compared to available BE values and other available assessment values (Aylward et al., 2013; St-Amand et al., 2014) to provide a cross-chemical evaluation of the relative levels of biomarker concentrations compared to risk assessment levels. Biomonitoring Equivalents (BEs) or other similar assessment values are available for a number of the analytes included in the California studies (Table 2) , enabling us to conduct a similar cross-chemical riskbased evaluation. For these analytes, GM biomarker concentration data from the California studies are generally well below the corresponding BE or other risk-based biomonitoring guidance values. Even at upper percentile values from these studies (90 th or 95th, depending upon the study) levels are consistently below the corresponding BE values in each case. For BPA, triclosan, specific phthalate metabolites, and PBDE 99, the GM levels reported in the California biomonitoring studies are 100's-to 1000's-fold lower than the BE values. For 2,4-dichlorophenoxyacteic acid, GM levels were 10,000-fold below the BE RfD . For hexachlorobenzene, cadmium and mercury, the GM levels are on the order of 4-to 50-fold lower than biomarker health risk-based guidance values. As discussed above, comparison of the upper percentiles to BE values may be appropriate for persistent compounds such as PFCs, PFAA, PBDEs, and legacy organochlorine compounds such as HCB. However, for highly transient compounds this comparison is likely to overestimate the relative level of longer-term exposure compared to the BE values for individuals in the population. Overall, the pattern of results suggest that exposures to the chemicals for which comparison values are available are occurring at levels well below the limits identified as being tolerable exposure levels.
Discussion
For many biomonitored chemicals, levels observed in the CA studies are generally similar to those observed in comparable subpopulations in the NHANES program. This should provide some confidence in the representativeness of the NHANES program results. Some differences for individual chemicals and for some chemical groups between the CA study results and the corresponding NHANES data were observed. Levels of some PAH compounds in urine varied from those observed in NHANES. These compounds can be markers of exposure to combustion-related substances, including smoking, air pollution and combustionrelated byproducts in food preparation (Li et al., 2010) . Biomarkers for these compounds are highly transient and sampled levels can vary widely within-and between-individuals over short time periods (Li et al., 2010) . Inspection of the available NHANES data over time also show that GM levels in the NHANES surveys have fluctuated substantially from one cycle to the next for some PAHs. This suggests that differences in biomarker concentrations for these compounds between studies or over time must be interpreted cautiously with respect to understanding longer-term average exposure levels.
The concentrations of lipophilic persistent compounds were frequently higher in the CTS study than in the other studies in CA, and higher than general reference values from the NHANES studies for adults. As previously noted, the CTS study likely includes a distribution of individuals that is older than in some of the studies of women of reproductive age, since the CTS study population consists of cases of women with breast cancer and matched controls (In the US, the median age of women at diagnosis of breast cancer is 61, and is most frequently diagnosed in women ages 55e64 [http://seer.cancer.gov/statfacts/html/breast.html]). Concentrations of lipophilic persistent compounds such as PCBs, DDT and metabolites, and HCB are generally higher in older individuals due to historically higher exposure levels (Patterson et al., 2009 ). Fig. 9 shows the CTS geometric mean results for selected PCBs, DDE, and HCB in comparison to age-group specific GMs for ages 40 to 59 and 60þ from NHANES as reported by Patterson et al. (2009) . The levels measured in the CTS study are similar to those reported in the NHANES dataset for adults in these age groups. Thus, this difference in levels observed in the main comparison of CTS results to those for all adults in NHANES are likely due to a shift in the age distribution in the CTS to older age on average than for all adults in NHANES.
Some PBDE compounds exhibited higher concentrations in the FOX and certain other CA studies than in the comparison NHANES data. The reasons for this are unknown. However, in the case of the FOX study, it is possible that as firefighters, the participants may be exposed to flame retardant materials released in fire situations at a rate higher than the general population. One of the greatest challenges faced in reporting human biomonitoring studies to stakeholders is interpretation of the results. In 2006, a National Academy of Sciences report on human biomonitoring (NRC, 2006) noted that "the ability to detect has outpaced the ability to interpret health risk," and recommended approaches to enhance risk-based interpretations (e.g., Chapter 5, NRC 2006). Subsequently, BEs were developed (Hays et al., 2007; Angerer et al., 2011) and used to interpret biomonitoring datasets, including the US NHANES data (Aylward et al., 2012) and data from the Canadian Health Measures Survey (St-Amand et al., 2014) .
We have now extended such analyses to the California Biomonitoring Program datasets. Health risk-based biomonitoring guidance values (e.g., BEs) were available for only a subset of the chemicals included in the studies collected through the California Biomonitoring Program. Comparison of the levels observed in these California studies to BEs (or similar biomonitoring interpretation guidance values) shows that in general, levels in the California studies are below or well below the corresponding assessment values. Even in cases where GM levels are higher in the California studies than in the NHANES datasets (e.g., for MnBP), the levels observed remain well below BE values or other risk assessmentbased biomonitoring interpretation standards, i.e. there is an adequate margin of safety.
For individual substances, such a hazard index interpretation approach is consistent with procedures used for evaluating potential human health risks from exposures (applied doses or intakes) in California's Air Toxics Hot Spots Program (http://oehha.ca. gov/air/hot_spots/2014/SRP2014/ SRPReviewSept2014GuidanceManual.pdf), California's drinking water programs (http://www.waterboards.ca.gov/drinking_water/ certlic/drinkingwater/MCLsandPHGs.shtml) and California's hazardous waste sites and permitted facilities program (http://www. dtsc.ca.gov/AssessingRisk/upload/HHRA-Note-3-2.pdf). Dourson et al. (2013) recommended that, to enhance interpretation and communication of biomonitoring results in the context of potential human health risks, biomonitoring investigations, such as those within the California Program, should utilize interpretation tools such as BEs, noting that interpretations based only on consideration of presence "should be actively discouraged."
Where differences in GM levels are observed between the CA studies and the NHANES datasets, these differences are generally within a half-order of magnitude (factor of 3) or less. To the extent that the observed differences represent long term differences in exposure levels, this magnitude of difference may be of concern if population exposure levels are near or above tolerable exposure levels based on toxicological data and risk assessment practices. However, this magnitude of difference tends to fall within the range of uncertainty in the development of such exposure guidance values, which typically include order-ofmagnitude uncertainty factors for inter-and intra-individual variations.
The pattern of results observed in the California studies reported to date in comparison to the NHANES program suggests that in general exposures in California for many compounds are generally similar to those found across the US, and where levels differ somewhat, the magnitude of difference is generally less than a factor of three. There are several implications of this observation. First, these results suggest that the general patterns of exposure for chemicals currently being biomonitored in the US may not differ to a great degree in different regions of the country. This suggests that, for purposes of providing a general indication of population exposure levels, smaller studies than NHANES may provide useful information. This conclusion depends of course on the degree of precision in exposure level required and the purpose of the specific exposure evaluation.
Second, these results suggest that studies in California designed to provide a population-representative sampling program (e.g., the developing BEST program) should consider including specific targeted objectives in order to supplement the overall goal of generating California population-representative data, since in many cases the data are likely to be very similar to those from the NHANES program. These objectives could include investigation of the apparent differences observed for selected analytes in the studies to date compared to the NHANES program, examination of supplementary classes of chemicals compared to those measured in the NHANES program, or measurement in specimens from population groups not widely represented in the NHANES program, e.g., children under 6.
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